Core Insights - Globus Medical reported revenue of $826.42 million for the quarter ended December 2025, reflecting a year-over-year increase of 25.7% and surpassing the Zacks Consensus Estimate by 4.9% [1] - The company's EPS for the quarter was $1.28, up from $0.84 in the same quarter last year, resulting in an EPS surprise of 20.76% compared to the consensus estimate of $1.06 [1] Revenue Breakdown - International revenues reached $161.1 million, exceeding the average estimate of $147.72 million by analysts, marking a 19% increase year-over-year [4] - U.S. revenues totaled $665.32 million, surpassing the average estimate of $621.92 million, with a year-over-year growth of 27.5% [4] Product Category Performance - Net sales from Enabling Technologies were $55.62 million, exceeding the average estimate of $33.7 million, representing an 18.5% increase year-over-year [4] - Net sales from Musculoskeletal Solutions amounted to $770.8 million, above the average estimate of $735.95 million, showing a year-over-year growth of 26.3% [4] Stock Performance - Shares of Globus Medical have returned +0.5% over the past month, while the Zacks S&P 500 composite has decreased by -1%, indicating potential outperformance in the near term [3]

Core Insights - Globus Medical, Inc. reported strong financial results for Q4 and the full year of 2025, with double-digit sales and earnings growth, driven by the successful integration of recent acquisitions and a focus on innovation [4][5]. Financial Performance - Q4 2025 worldwide net sales reached $826.4 million, a 25.7% increase from Q4 2024, with U.S. net sales up 27.5% and international sales up 19.0% [4][5]. - For the full year 2025, worldwide net sales totaled $2,938.9 million, reflecting a 16.7% increase over 2024, with U.S. sales increasing by 18.4% and international sales by 10.0% [5][6]. - GAAP net income for Q4 2025 was $140.6 million, a significant increase of 430.4% year-over-year, primarily due to higher sales and contributions from the Nevro acquisition [6][7]. - Non-GAAP diluted EPS for Q4 2025 was $1.28, up 52.1% from $0.84 in Q4 2024 [7][8]. Business Segments - The U.S. Spine business grew revenue by 10% in Q4 2025 compared to the prior year, while Enabling Technologies saw a remarkable growth of 19% [4][6]. - For the full year, Musculoskeletal Solutions generated $2,797.9 million in sales, while Enabling Technologies contributed $141.0 million [31]. Guidance and Future Outlook - The company reaffirmed its 2026 revenue guidance in the range of $3.18 to $3.22 billion and updated its non-GAAP fully diluted EPS guidance to $4.40 to $4.50 [9]. - The focus for 2026 includes scaling growth, expanding the sales force, and launching a robust new product pipeline to address unmet clinical needs [4][9]. Cash and Liquidity - As of December 31, 2025, cash and cash equivalents were $526.2 million, down from $784.4 million in 2024, with total cash, cash equivalents, and marketable securities at $629.1 million [33]. - The company generated $753.4 million in net cash from operating activities for the year, a significant increase from $520.6 million in 2024 [28]. Integration and Strategic Initiatives - The successful integration of NuVasive and Nevro has been highlighted as a key driver of value creation and market penetration [4][6]. - The company aims to enhance surgical outcomes through its Globus surgical intelligence closed-loop ecosystem, which integrates patient selection, surgical techniques, and complementary implants [4].

Core Insights - Wall Street analysts forecast that Globus Medical (GMED) will report quarterly earnings of $1.06 per share, reflecting a year-over-year increase of 26.2% [1] - Anticipated revenues for the quarter are projected to be $787.85 million, indicating a 19.9% increase compared to the same quarter last year [1] Earnings Estimates - The consensus EPS estimate has remained unchanged over the last 30 days, indicating a collective reevaluation by analysts [2] - Changes in earnings estimates are crucial for predicting investor reactions to the stock, with empirical studies showing a strong relationship between earnings estimate revisions and short-term price performance [3] Key Metrics Projections - Analysts project 'Net Sales by Product Category- Enabling Technologies' to reach $33.70 million, a decrease of 28.2% from the prior-year quarter [5] - The average estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' is $735.95 million, suggesting a year-over-year increase of 20.6% [5] - Estimated 'Geographic Revenues- International' are projected at $147.72 million, reflecting a 9.1% increase year over year [6] - 'Geographic Revenues- United States' are expected to reach $621.92 million, indicating a 19.2% increase from the year-ago quarter [6] Stock Performance - Globus Medical shares have experienced a decline of 4.3% in the past month, compared to a 0.8% decline in the Zacks S&P 500 composite [6] - With a Zacks Rank 2 (Buy), GMED is expected to outperform the overall market performance in the near term [6]

Core Insights - Globus Medical reported revenue of $769.05 million for the quarter ended September 2025, reflecting a year-over-year increase of 22.9% [1] - The company's EPS was $1.18, up from $0.83 in the same quarter last year, indicating a significant improvement [1] - The reported revenue exceeded the Zacks Consensus Estimate of $733.45 million by 4.85%, while the EPS surpassed the consensus estimate of $0.79 by 49.37% [1] Revenue Breakdown - International revenue reached $151.42 million, exceeding the average estimate of $144.37 million by analysts, marking a 16.6% increase year-over-year [4] - U.S. revenue was reported at $617.63 million, surpassing the average estimate of $589.84 million, with a year-over-year growth of 24.6% [4] - Net sales in the Enabling Technologies category were $28.04 million, below the average estimate of $40.23 million, representing a decline of 26.8% year-over-year [4] - Musculoskeletal Solutions generated $741.01 million in net sales, exceeding the average estimate of $693.98 million, with a year-over-year increase of 26.2% [4] Stock Performance - Shares of Globus Medical have returned +1.8% over the past month, compared to a +1.3% change in the Zacks S&P 500 composite [3] - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3]

Core Insights - Globus Medical, Inc. reported a strong financial performance for Q3 2025, with revenue increasing by 23% year-over-year, driven by a 10% growth in the US Spine business and strong demand across products and geographies [2][3] - The company achieved record non-GAAP free cash flow of $213.9 million, up 24% quarter-over-quarter, and non-GAAP diluted earnings per share of $1.18, a 43% increase compared to the same quarter last year [2][4] - The company raised its full-year 2025 revenue guidance to a range of $2.86 to $2.90 billion and non-GAAP fully diluted earnings per share to a range of $3.75 to $3.85, indicating confidence in future growth [5] Financial Performance - Worldwide net sales for Q3 2025 were $769.0 million, a 22.9% increase from Q3 2024, with US net sales rising by 24.6% and international sales increasing by 16.5% [2][7] - GAAP net income for Q3 2025 was $119.0 million, reflecting a 129.5% increase year-over-year, primarily due to higher sales, including $99.3 million from the Nevro acquisition [3][7] - Non-GAAP diluted EPS for Q3 2025 was $1.18, up 42.6% from $0.83 in Q3 2024 [3][40] Cash Flow and Capital Management - Net cash provided by operating activities was $249.7 million for Q3 2025, contributing to a non-GAAP free cash flow of $213.9 million [4][43] - The company executed share repurchases totaling $40 million in the quarter, bringing the total for the first nine months of 2025 to $255.5 million, demonstrating a commitment to shareholder value [2][4] Strategic Acquisitions - The integration of the recently acquired Nevro business has exceeded expectations, contributing significantly to revenue growth and underscoring the effectiveness of the company's integration strategy [2][3] - The Nevro acquisition is expected to be accretive to earnings in 2025, further enhancing the company's growth prospects [5] Market Position and Outlook - The company remains focused on achieving consistent organic growth through innovation and disciplined execution, aiming to finish 2025 strong [2][5] - The strong performance in Q3 highlights the company's ability to balance growth with operational efficiency and synergy execution [2][3]

Core Insights - Globus Medical, Inc. (GMED) reported second-quarter 2025 adjusted earnings per share (EPS) of 86 cents, exceeding the Zacks Consensus Estimate by 13.16% and reflecting a year-over-year increase of 14.1% [1][9] - The company's revenues for the quarter reached $745.3 million, marking an 18.4% increase year over year and surpassing the Zacks Consensus Estimate by 0.49% [3][9] - GMED's gross profit rose 34.3% year over year to $496.6 million, with a gross margin expansion of 792 basis points to 66.6% [6][9] Revenue Performance - Worldwide sales increased to $745.3 million, driven by a $95 million contribution from the recently acquired Nevro [3][9] - U.S. net sales grew 20.3% year over year to $600.8 million, while international revenues rose 11% to $144.6 million [4] Product Performance - Musculoskeletal Solutions generated revenues of $710.2 million, up 19.8% year over year, while Enabling Technologies saw a decline of 4.4% to $35.2 million [5] Margin and Profitability - Adjusted operating profit was $153 million, a 65.4% increase from the previous year, with an adjusted operating margin of 20.5% [7] - SG&A expenses increased by 26.8% to $303.6 million, while research and development expenses rose 5.9% to $40 million [6] Cash Position - At the end of Q2 2025, GMED had combined cash and cash equivalents of $229.4 million, down from $461.3 million at the end of Q1 [8] - Net cash provided by operating activities was $255.2 million, compared to $106.6 million in the prior year [8] Guidance - GMED reaffirmed its full-year 2025 guidance, projecting net sales between $2.80 billion and $2.90 billion, with adjusted EPS expected in the range of $3.00 to $3.30 [10] Market Position - The company experienced strong momentum in the U.S. Spine business, achieving its highest sequential revenue growth since Q2 2022, with notable growth in the EMEA region [11] - GMED is increasing investment and output to enhance product delivery and engagement with surgeon partners [12]

Core Insights - Globus Medical reported revenue of $745.34 million for the quarter ended June 2025, marking an 18.4% year-over-year increase and exceeding the Zacks Consensus Estimate of $741.7 million by 0.49% [1] - The company's EPS for the same period was $0.86, up from $0.75 a year ago, and also surpassed the consensus EPS estimate of $0.76 by 13.16% [1] Revenue Breakdown - International revenues reached $144.56 million, exceeding the average estimate of $140.52 million, reflecting an 11% year-over-year increase [4] - U.S. revenues totaled $600.78 million, surpassing the average estimate of $586.71 million, with a year-over-year growth of 20.3% [4] Product Category Performance - Net sales from Enabling Technologies were $35.16 million, below the five-analyst average estimate of $37.43 million, representing a decline of 4.4% year-over-year [4] - Net sales from Musculoskeletal Solutions amounted to $710.18 million, exceeding the average estimate of $679.67 million, with a year-over-year increase of 19.8% [4] Stock Performance - Shares of Globus Medical have declined by 7.8% over the past month, contrasting with the Zacks S&P 500 composite's increase of 1.2% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Insights - Globus Medical, Inc. reported strong financial results for Q2 2025, with worldwide net sales reaching $745.3 million, an increase of 18.4% year-over-year [2][7]. - The U.S. Spine business was a significant contributor, growing by 5.7% as reported and 7.4% on a day-adjusted basis, marking the highest sequential revenue growth since Q2 2022 [2][3]. - The company achieved a GAAP net income of $202.8 million, a remarkable increase of 538.7% compared to the same period last year, primarily due to a bargain purchase gain of $110.6 million [3][7]. Financial Performance - Q2 2025 non-GAAP diluted EPS was $0.86, up 14.1% from $0.75 in Q2 2024, while GAAP diluted EPS was $1.49 compared to $0.23 in the prior year [3][39]. - Operating cash flow for Q2 2025 was $77.9 million, with non-GAAP free cash flow at $31.3 million [4][41]. - The company reaffirmed its full-year 2025 revenue guidance in the range of $2.80 to $2.90 billion and non-GAAP fully diluted EPS guidance of $3.00 to $3.30 [5]. Business Strategy - The company is focused on accelerating deal timelines from its pipeline to establish robotic-assisted surgery as the standard of care [2]. - Investment in new product launches and competitive recruiting for the sales force remains a priority to drive organic growth [2][3]. - The integration of the recently acquired Nevro, Inc. is underway, with efforts to identify and execute synergy actions [3]. Market Position - The company reported above-market growth in its base business during Q2 2025, indicating strong operational efficiency and a focus on long-term profitable growth [2][3]. - International net sales increased by 11.0% year-over-year, with a 7.5% increase on a constant currency basis [2][7]. Product Performance - Musculoskeletal Solutions generated $710.2 million in sales for Q2 2025, up from $592.9 million in Q2 2024 [25]. - Enabling Technologies saw a slight decline in sales, with Q2 2025 sales at $35.2 million compared to $36.8 million in Q2 2024 [25]. Liquidity and Capital Resources - As of June 30, 2025, cash and cash equivalents were reported at $229.4 million, down from $784.4 million at the end of 2024 [19][27]. - The total cash, cash equivalents, and marketable securities amounted to $229.4 million, significantly lower than $956.2 million at the end of 2024 [27].

Core Insights - Wall Street analysts forecast that Globus Medical (GMED) will report quarterly earnings of $0.76 per share, reflecting a year-over-year increase of 1.3% and revenues of $741.7 million, which is an increase of 17.8% compared to the previous year [1] Earnings Estimates - Over the last 30 days, there has been a downward revision of 0.7% in the consensus EPS estimate for the quarter, indicating a collective reconsideration by covering analysts [2] - Changes in earnings estimates are crucial for predicting potential investor reactions, with empirical studies showing a strong relationship between earnings estimate revisions and short-term stock price performance [3] Revenue Projections - Analysts project 'Net Sales by Product Category- Enabling Technologies' at $37.43 million, suggesting a year-over-year change of +1.8% [5] - The consensus estimate for 'Net Sales by Product Category- Musculoskeletal Solutions' is $679.67 million, indicating a year-over-year change of +14.6% [5] - 'Geographic Revenues- International' is expected to reach $140.52 million, reflecting a change of +7.9% from the year-ago quarter [5] - 'Geographic Revenues- United States' is projected to be $586.71 million, suggesting a year-over-year change of +17.5% [6] Stock Performance - Shares of Globus Medical have experienced a change of -5.2% in the past month, contrasting with the +0.5% move of the Zacks S&P 500 composite [6] - With a Zacks Rank 4 (Sell), GMED is expected to underperform the overall market in the near future [6]

Core Viewpoint - Globus Medical reported a decline in revenue and earnings for the quarter ended March 2025, missing Wall Street expectations, indicating potential challenges in financial performance [1][2]. Financial Performance - Revenue for the quarter was $598.12 million, down 1.4% year-over-year, and below the Zacks Consensus Estimate of $628.32 million by 4.81% [1]. - Earnings per share (EPS) were $0.68, a decrease from $0.72 in the same quarter last year, and fell short of the consensus estimate of $0.74 by 8.11% [1]. Geographic Revenue Breakdown - International revenue was reported at $114.26 million, which is 7.7% lower than the three-analyst average estimate of $127.52 million [4]. - U.S. revenue stood at $483.86 million, slightly up by 0.2% year-over-year, but below the average estimate of $510.72 million [4]. Product Category Performance - Net sales from Enabling Technologies were $22.19 million, significantly lower than the estimated $38.79 million, reflecting a year-over-year decline of 30.6% [4]. - Musculoskeletal Solutions generated $575.93 million in sales, which was marginally above the year-ago figure by 0.2%, but still below the estimated $598.85 million [4]. Stock Performance - Shares of Globus Medical have returned -3.7% over the past month, contrasting with the Zacks S&P 500 composite's increase of 11.3% [3]. - The stock currently holds a Zacks Rank 3 (Hold), suggesting it may perform in line with the broader market in the near term [3].